Global Neurology Academy

Strengthening Global Infrastructure for FSHD Trials
Strengthening Global Infrastructure for FSHD Trials
AudioAbstracts
Strengthening Global Infrastructure for FSHD Trials
- Marlene Mimi Maeusli, PhD.
The Burden of Cognitive Dysfunction in Multiple Sclerosis
The Burden of Cognitive Dysfunction in Multiple Sclerosis
NeuroFrontiers
The Burden of Cognitive Dysfunction in Multiple Sclerosis
- Christopher Lock, MD
Switching to Risdiplam Maintains Motor Gains in SMA Patients
Switching to Risdiplam Maintains Motor Gains in SMA Patients
AudioAbstracts
Switching to Risdiplam Maintains Motor Gains in SMA Patients
- Ryan Quigley
Who’s Missing from Multiple Sclerosis Research?
Who’s Missing from Multiple Sclerosis Research?
NeuroFrontiers
Who’s Missing from Multiple Sclerosis Research?
- Ashley Baker, MSN, PMHNP
- Ruth Ann Marrie, MD, PhD
GFAP and VEGF Trajectories in Adult Type 3 Spinal Muscular Atrophy Under Nusinersen
GFAP and VEGF Trajectories in Adult Type 3 Spinal Muscular Atrophy Under Nusinersen
NeuroFrontiers
GFAP and VEGF Trajectories in Adult Type 3 Spinal Muscular Atrophy Under Nusinersen
Understanding Accelerated Biological Aging in Pediatric MS
Understanding Accelerated Biological Aging in Pediatric MS
NeuroFrontiers
Understanding Accelerated Biological Aging in Pediatric MS
- Jennifer Yang, MD
Multiplex Proteomic Biomarkers in MS: Emerging Tools for Precision Care
Multiplex Proteomic Biomarkers in MS: Emerging Tools for Precision Care
NeuroFrontiers
Multiplex Proteomic Biomarkers in MS: Emerging Tools for Precision Care
- Raphael Schneider, MD, PhD, FRCPC, CIP
Advancing MS Care with Multimodal Aging Signatures and Proteomic Biomarkers
Advancing MS Care with Multimodal Aging Signatures and Proteomic Biomarkers
NeuroFrontiers
Advancing MS Care with Multimodal Aging Signatures and Proteomic Biomarkers
- Adil Harroud, MD
- Dylan Hamitouche
- Ryan Quigley

Medical News

Medical News
Evoke and Evoke+: Oral Semaglutide in Early Alzheimer's Disease
03/24/2026
Read more
Medical News
Microglial Fructose Metabolism and Immune Suppression in Glioblastoma
03/19/2026
Read more
Medical News
GRIN2A Mutation Linked to Impaired Belief Updating in Schizophrenia
03/19/2026
Read more
Medical News
Racial and Biological Diversity in Early Alzheimer Brain Markers
03/16/2026
Read more

See more news

CME/CE

CME/CE In-Person Event
Moving Beyond Sleep: The Broader Connection Between the Orexin System and Psychiatric Disorders
May 27, 2026
Miami Beach, Florida
1.00 credit Learn more
Moving Beyond Sleep: The Broader Connection Between the Orexin System and Psychiatric Disorders
Moving Beyond Sleep: The Broader Connection Between the Orexin System and Psychiatric Disorders
CME/CE In-Person Event
Moving Beyond Sleep: The Broader Connection Between the Orexin System and Psychiatric Disorders
May 27, 2026
Miami Beach, Florida
1.00 credit Learn more
Advancing gMG Clinical Decisions: Diagnosing Early, Treating Smarter, and Caring Holistically – A Case-Based Treatment Approach
Advancing gMG Clinical Decisions: Diagnosing Early, Treating Smarter, and Caring Holistically – A Case-Based Treatment Approach
CME/CE
Advancing gMG Clinical Decisions: Diagnosing Early, Treating Smarter, and Caring Holistically – A Case-Based Treatment Approach
0.25 credits
- Christyn Edmundson, MD
- Neelam Goyal, MD
0.25 credits
Optimizing the Role for Corticosteroids Within the Evolving DMD Treatment Landscape
Optimizing the Role for Corticosteroids Within the Evolving DMD Treatment Landscape
CME/CE
Optimizing the Role for Corticosteroids Within the Evolving DMD Treatment Landscape
1.00 credit
- Stephen Chrzanowski, MD, PhD
- Aravindhan Veerapandiyan, MD
1.00 credit

Clinical Practice

Early ALS Patients Show Slowed Decline with Pridopidine Treatment
Early ALS Patients Show Slowed Decline with Pridopidine Treatment
NeuroFrontiers
Early ALS Patients Show Slowed Decline with Pridopidine Treatment
CK1δ Inhibition and Riluzole in ALS: Synergy at Lower Doses
CK1δ Inhibition and Riluzole in ALS: Synergy at Lower Doses
NeuroFrontiers
CK1δ Inhibition and Riluzole in ALS: Synergy at Lower Doses
Multiple Sclerosis Without Borders: Taking a Global View
Multiple Sclerosis Without Borders: Taking a Global View
NeuroFrontiers
Multiple Sclerosis Without Borders: Taking a Global View
- Andrew Wilner, MD, FACP, FAAN
- Victor Rivera, MD
Beyond the Primary Endpoint: What OCEANIC-STROKE Subtype Analyses Reveal About Asundexian’s Potential
Beyond the Primary Endpoint: What OCEANIC-STROKE Subtype Analyses Reveal About Asundexian’s Potential
Global Neurology Academy
Beyond the Primary Endpoint: What OCEANIC-STROKE Subtype Analyses Reveal About Asundexian’s Potential
- Ashkan Shoamanesh, MD

Programs

Spinal Muscular Atrophy Reveals Hidden Kidney Impairment Risk
Spinal Muscular Atrophy Reveals Hidden Kidney Impairment Risk
NeuroFrontiers
Spinal Muscular Atrophy Reveals Hidden Kidney Impairment Risk
Rethinking Progression in Multiple Sclerosis
Rethinking Progression in Multiple Sclerosis
NeuroFrontiers
Rethinking Progression in Multiple Sclerosis
- Charles Turck, PharmD, BCPS, BCCCP
- Christopher Lock, MD
Vitamin D3's Effects on Inflammatory and Oxidative Biomarkers in MS
Vitamin D3's Effects on Inflammatory and Oxidative Biomarkers in MS
NeuroFrontiers
Vitamin D3's Effects on Inflammatory and Oxidative Biomarkers in MS
Optimizing Vitamin D Supplementation in MS Care
Optimizing Vitamin D Supplementation in MS Care
NeuroFrontiers
Optimizing Vitamin D Supplementation in MS Care